Videos

Dr. Ian Flinn explains that as a Bruton's tyrosine kinase (BTK) therapy, zanubrutinib provides an option with reduced adverse events compared with chemotherapy treatments like venetoclax.

“Our primary motivation was to help develop treatments for people with osteoarthritis that would slow or prevent the disease and be more than painkillers- actually affect the disease process itself,” Virginia Kraus, MD, explains.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi's long-term dedication to biosimilars.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

The latest HCPLive interview segment with Karan Lal, DO, discussing his views on what can go wrong during cosmetic procedures.

A new interview segment with Karan Lal, DO, in which he explores the benefits and drawbacks of dermatology offices versus medical spas.

Falloon said IBD-associated peripheral arthritis is common, but not well understood.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

A discussion with Henry Lim, MD, during an interview segment in which he described photoprotection measures for various skin phenotypes and his outlook on future research.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

An interview segment on HCPLive with James Del Rosso, DO, in which he explores key highlights from his presentation at the 2023 Winter Clinical conference.

An HCPLive interview with Henry Lim, MD, during which he describes the differing needs of various skin types and the differences in sunscreen regulations.

An interview segment with Henry Lim, MD, on his presentation from Winter Clinical regarding different photoprotection measures for different phenotypes.

In a segment of his HCPLive interview regarding his Winter Clinical presentation, James Del Rosso, DO, highlighted several points about acne and rosacea treatment.

This segment of Raj Chovatiya’s interview with HCPLive, a discussion was conducted regarding facts about abrocitinib for atopic dermatitis treatment.

During an HCPLive interview on his presentation at Winter Clinical, Raj Chovatiya discussed the use of abrocitinib on atopic dermatitis patients.

An interview segment featuring Lal’s experiences treating epidermolysis bullosa as well as his opinions on treatment and management.

An interview with Karan Lal on his experiences treating patients facing the rare condition known as epidermolysis bullosa.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.

An interview segment with Armstrong in which she elaborates on some of the main points made from her presentation on psoriasis treatments.

More patients are presenting with later stage liver cancer due to missed screenings during the COVID-19 pandemic.

Michael J. Ackerman, MD, PhD, discusses the simplicity and availability of education around CPR and defibrillator use, and the role of clinicians in raising public health preparedness.

A Mayo Clinic cardiologist discusses the national variability in CPR and AED access, and the actions that saved Hamlin's life during Monday Night Football.

"The challenge right now is that we have no therapies in the emergency department to treat acute pain, outside of pain medications and IV opioids," Dr. Claudia Morris says in an interview.

The motive of the study wasn't to implement hematopoietic stem cell transplantation (HSCT) programs worldwide, but as a contribution to comprehensive cancer control efforts.

According to Dr. Corinna Schultz, a key part of the conversation of sickle cell trait (SCT) is centered around reproductive choices for the patient in the future.